Se connecter

Bibliographies thématiques / Multiple myeloma Chemotherapy

Sommaire

Articles de revues
Thèses
Livres
Chapitres de livres
Actes de conférences
Rapports d'organisations

Littérature scientifique sur le sujet « Multiple myeloma Chemotherapy »

Auteur : Grafiati

Publié le 4 juin 2021

Mis à jour le 30 janvier 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Multiple myeloma Chemotherapy ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Multiple myeloma Chemotherapy"

1

Durie, Brian G. M. "Chemotherapy of multiple myeloma." Baillière's Clinical Haematology 4, no. 1 (January 1991): 181–95. http://dx.doi.org/10.1016/s0950-3536(05)80290-2.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Kogan, Michael, and Adnan H. Siddiqui. "Intracranial Multiple Myeloma After Chemotherapy." Archives of Clinical and Medical Case Reports 01, no. 02 (2017): 42–44. http://dx.doi.org/10.26502/acmcr.9655008.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Lokhorst, H. M., O. J. A. Th Meuwissen, E. J. E. G. Bast, and A. W. Dekker. "VAD chemotherapy for refractory multiple myeloma." British Journal of Haematology 71, no. 1 (January 1989): 25–30. http://dx.doi.org/10.1111/j.1365-2141.1989.tb06269.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Peest, D., H. J. Schmoll, I. Schedel, S. Glück, K. Schumacher, and H. Deicher. "VBAMDex chemotherapy in advanced multiple myeloma*." European Journal of Haematology 40, no. 3 (April 24, 2009): 245–49. http://dx.doi.org/10.1111/j.1600-0609.1988.tb00831.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Terrovitis, John V., Charis Matsouka, Athanassios Anagnostopoulos, Maria I. Anastasiou-Nana, and Athanassios Meletios Dimopoulos. "Hemophagocytic Lymphohistiocytosis After Chemotherapy for Multiple Myeloma." Clinical Lymphoma 5, no. 3 (December 2004): 194–96. http://dx.doi.org/10.3816/clm.2004.n.026.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Alexanian, Raymond, Bart Barlogie, and Gerard Ventura. "Chemotherapy for resistant and relapsing multiple myeloma." European Journal of Haematology 43, S51 (April 24, 2009): 140–44. http://dx.doi.org/10.1111/j.1600-0609.1989.tb01507.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Vidarsson, Brynjar, Svanhvit Olafsdottir, and Sigrun Reykdal. "VASP Chemotherapy in Patients with Multiple Myeloma." Blood 106, no. 11 (November 16, 2005): 5189. http://dx.doi.org/10.1182/blood.v106.11.5189.5189.

Texte intégral

Résumé :

Abstract Introduction: Multiple myeloma (MM) is a malignant disorder of plasma cells resistant to chemotherapy. Various chemotherapy protocols are available for patients with MM, including VAD (vincristine, adriamycin, prednisolon) and MP (melphalan, prednisolon). These therapies aim to slow disease progression and/or prepare the patient for stem cell transplantation (SCT), the standard of care for MM patients younger than 70. An additional regimen, VASP, consisting of etoposide 50mg/m2 IV on day 1 and 100mg/m2 PO on days 2–4, adriamycin 25mg/m2 IV on day 1, cyclophosphamide 500mg/m2 IV on day

Styles APA, Harvard, Vancouver, ISO, etc.

8

Minařík, Jiří, and Sabina Ševčíková. "Immunomodulatory Agents for Multiple Myeloma." Cancers 14, no. 23 (November 23, 2022): 5759. http://dx.doi.org/10.3390/cancers14235759.

Texte intégral

Résumé :

The treatment of multiple myeloma (MM) has undergone a significant paradigm shift in the last 20 years, from conventional chemotherapy to more tumor-specific treatments, based on the interference with pathogenesis of the malignant clone as well as the bone microenvironment [...]

Styles APA, Harvard, Vancouver, ISO, etc.

9

Katagiri, Daisuke, Eisei Noiri, and Fumihiko Hinoshita. "Multiple Myeloma and Kidney Disease." Scientific World Journal 2013 (2013): 1–9. http://dx.doi.org/10.1155/2013/487285.

Texte intégral

Résumé :

Multiple myeloma (MM) has a high incidence rate in the elderly. Responsiveness to treatments differs considerably among patients because of high heterogeneity of MM. Chronic kidney disease (CKD) is a common clinical feature in MM patients, and treatment-related mortality and morbidity are higher in MM patients with CKD than in patients with normal renal function. Recent advances in diagnostic tests, chemotherapy agents, and dialysis techniques are providing clinicians with novel approaches for the management of MM patients with CKD. Once reversible factors, such as hypercalcemia, have been cor

Styles APA, Harvard, Vancouver, ISO, etc.

10

Bensinger, William I. "Hematopoietic Cell Transplantation for Multiple Myeloma." Cancer Control 5, no. 3 (May 1998): 235–42. http://dx.doi.org/10.1177/107327489800500304.

Texte intégral

Résumé :

Background Multiple myeloma (MM) is a malignant plasma cell disorder with a median survival of three years. Despite the development of numerous conventional chemotherapy regimens and interferons, there has been little progress in improving the survival of patients with MM. Very high-dose chemoradiotherapy and autologous or allogeneic hematopoetic stem cell transplantation (HSCT) can result in high complete remission rates, even in patients with advanced disease. Methods A prospective, randomized study has shown that autologous HSCT results in superior response rates, progression-free survival,

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Thèses sur le sujet "Multiple myeloma Chemotherapy"

1

Turner, Joel G. "Drug resistance to topoisomerase directed chemotherapy in human multiple myeloma." [Tampa, Fla] : University of South Florida, 2008. http://purl.fcla.edu/usf/dc/et/SFE0002446.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Redzepovic, Jasmina [Verfasser]. "Meta-analysis in context : Chemotherapy versus chemotherapy combined with bisphosphonate therapy in multiple myeloma patients / Jasmina Redzepovic." Berlin : Freie Universität Berlin, 2009. http://d-nb.info/1023664585/34.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Viziteu, Elena. "RECQ1 Helicase Involvement in the Resistance to Replication Stress and Chemotherapy in Multiple Myeloma Myélome Multiple." Thesis, Montpellier, 2015. http://www.theses.fr/2015MONTT008.

Texte intégral

Résumé :

Le myélome multiple (MM) est une néoplasie B caractérisée par l’accumulation d’un clone plasmocytaire dans la moelle osseuse. Des études ont démontré que les modifications épigénétiques comme la méthylation de l’ADN jouent un rôle dans la régulation d’expression de différents gènes associés au cancer. Dans une étude récente, nous avons pu décrire un score génique de méthylation de l’ADN permettant de prédire la sensibilité des cellules de MM aux inhibiteurs de DNMT (DNA methyltranfexrase) (Moreaux, et al 2012). Parmi les gènes dont l’expression est inhibée par les inhibiteurs de DNMT et associ

Styles APA, Harvard, Vancouver, ISO, etc.

4

Pan, Beiqing. "Mechanisms of skeletal disease mediated by haematological malignancies /." Title page, table of contents and abstract only, 2004. http://web4.library.adelaide.edu.au/theses/09PH/09php1871.pdf.

Texte intégral

Résumé :

Thesis (Ph.D.)--University of Adelaide, Dept. of Medicine and The Hanson Centre, Institute of Medical and Veterinary Science, 2004.<br>"August 2004" Errata inside front cover. Bibliography: leaves 126-159.

Styles APA, Harvard, Vancouver, ISO, etc.

5

Pan, Beiqing. "Molecular and cellular studies of zoledronic acid : a potent inhibitor of multiple myeloma-induced osteolysis." Title page, contents and abstract only, 2002. http://web4.library.adelaide.edu.au/theses/09MSM/09msmp187.pdf.

Texte intégral

Résumé :

Bibliography: leaves 86-103. Investigates the effect of zoledronic acid on myeloma cells and osteoblast-like cells to establish the molecular and cellular mechanisms responsible for the clinical effectiveness of bisphosphonates in the treatment of patients with myelomatosis. Concludes that zoledronic acid inhibits myelomatosis-induced osteolysis thorugh the mechanisms of myeloma cell death and proliferation and maturation of osteoblasts.

Styles APA, Harvard, Vancouver, ISO, etc.

6

Nikolich‐Zugich, Tijana. "Effects of High Vs. Reduced‐Dose Melphalan For Autologous Bone Marrow Transplantation in Multiple Myeloma On Pulmonary Function: A Longitudinal Study." Thesis, The University of Arizona, 2017. http://hdl.handle.net/10150/623514.

Texte intégral

Résumé :

A Thesis submitted to The University of Arizona College of Medicine - Phoenix in partial fulfillment of the requirements for the Degree of Doctor of Medicine.<br>Bone marrow transplants (BMT, also hematopoietic stem cell transplants or HSCT/SCT) are one of the greatest medical achievements of the 20th century. They offer a treatment for a host of malignant and nonmalignant hematopoietic disorders, genetic diseases and solid tumors that could otherwise be fatal. Studies have found that 60% of patients undergoing BMT develop pulmonary complications (PC), and 1/3 of those require intensive care a

Styles APA, Harvard, Vancouver, ISO, etc.

7

Sezer, Orhan. "Angiogenese und Knochenstoffwechsel beim multiplen Myelom." Doctoral thesis, [S.l.] : [s.n.], 2001. http://deposit.ddb.de/cgi-bin/dokserv?idn=963183303.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Andrews, S. W. "Genotoxicity and functionality assessment of a bone marrow stromal cell line following chemotherapy exposure in an in vitro model of multiple myeloma." Thesis, University of the West of England, Bristol, 2017. http://eprints.uwe.ac.uk/30035/.

Texte intégral

Résumé :

Multiple myeloma (MM) is a haematological malignancy characterized by terminally differentiated plasma cells and their accumulation in the bone marrow (BM). Despite significant advances in therapeutic strategies it currently remains incurable. The interactions between the BM microenvironment and malignant plasma cells have been pivotal to understanding this disease. Previous reports have shown that patients with a haematological malignancy sustain “damage” to their BM, but how much of this is due to the disease and/or the treatment is currently unknown. Furthermore MM plasma cells have been do

Styles APA, Harvard, Vancouver, ISO, etc.

9

Cachia, Elaine. "The involvement of the central nervous system in chemotherapy-induced peripheral neuropathy, and the symptom burden and health-related quality of life in patients with multiple myeloma." Thesis, University of Sheffield, 2013. http://etheses.whiterose.ac.uk/3885/.

Texte intégral

Résumé :

Background: Modern treatments extend life expectancy in patients with multiple myeloma (MM) and a high incidence of chemotherapy-induced peripheral neuropathy (CIPN) has evolved. The impact of disease and treatment on health-related quality of life (HRQoL) in MM is poorly characterised. This work aimed to investigate (i) the neuroanatomical functional correlates of pain processing in CIPN and (ii) HRQoL and symptom burden in advanced, intensively-treated myeloma. Methods: First study: twelve neurophysiologically assessed patients with CIPN and 12 healthy volunteers underwent fMRI to determine

Styles APA, Harvard, Vancouver, ISO, etc.

10

Strifler, Susanne [Verfasser], and Stefan [Gutachter] Knop. "Eine späte, dritte Hochdosis-Chemotherapie als wirksame Rezidivbehandlung des fortgeschrittenen multiplen Myeloms / Susanne Strifler ; Gutachter: Stefan Knop." Würzburg : Universität Würzburg, 2018. http://d-nb.info/1159881219/34.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Livres sur le sujet "Multiple myeloma Chemotherapy"

1

Anderson, Kenneth C., Paul G. Richardson, and Irene M. Ghobrial. Bortezomib in the treatment of multiple myeloma. Basel: Springer, 2010.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Inc, ebrary, ed. Towards individualized therapy for multiple myeloma: A guide for choosing treatment that best fits patients. Singapore: World Scientific Publishing Co., 2009.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Ozon, Lynn. A retrospective analysis of febrile neutropenia in patients with multiple myeloma and lymphoma treated with high-dose chemotherapy and autologous bone marrow transplant in the outpatient setting. c2003, 2003.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Kuypers, Dirk R. J., and Morie A. Gertz. Light-chain deposition disease. Edited by Giuseppe Remuzzi. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0154_update_001.

Texte intégral

Résumé :

Light-chain deposition disease (LCDD) is characterized by extracellular tissue deposition of non-amyloid monoclonal immunoglobulin light chains (predominantly kappa light chains) in various organs including kidneys, heart, and liver. It is a rare cause of renal insufficiency. In two-thirds of cases it is associated with multiple myeloma, while in the remainder their monoclonal B cell proliferation does not meet the criteria for that diagnosis.Renal involvement occurs almost invariably and dominates the clinical course of the disease: greater than 90% of patients with LCDD have renal functional

Styles APA, Harvard, Vancouver, ISO, etc.

Chapitres de livres sur le sujet "Multiple myeloma Chemotherapy"

1

Manier, Salomon, Artur Jurczyszyn, and David H. Vesole. "Bridging Chemotherapy: Multiple Myeloma." In The EBMT/EHA CAR-T Cell Handbook, 127–29. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-94353-0_24.

Texte intégral

Résumé :

AbstractIn the phase 2 KarMMa study, 88% of the patients received bridging therapy with only a 5% response (Munshi et al. 2021). In the CARTITUDE 1 trial, 75% of the patients received bridging therapy, with a reduction in tumour burden observed in 34% of the patients prior to cilta-cel infusion, but no patients achieved a CR or better while on bridging therapy (Madduri et al. 2019). Bridging therapy is recommended for virtually all patients. An exception can be discussed for patients with slowly progressive disease, who may not need to receive bridging therapy after leukapheresis; however, this strategy exposes them to a risk of rapid progression later during the manufacturing period. In the future, with allogeneic CAR-T cells, bridging therapy will likely not be necessary because the time between patient inclusion and CAR-T cell infusion is much reduced.

Styles APA, Harvard, Vancouver, ISO, etc.

2

Fermand, J. P., Y. Levy, M. Adam, X. Sithy, J. M. Miclea, S. Chevret, J. Gerota, M. Benbunan, M. Seligmann, and J. C. Brouet. "High Dose Chemotherapy and Blood Stem Cell Autologous Graft in Multiple Myeloma." In Advances in haemapheresis, 139–44. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4615-3904-9_17.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Riordan, Neil H., Thomas E. Ichim, Famela Ramos, Samantha Halligan, Rosalia De Necochea-Campion, Grzegorz W. Basak, Steven F. Josephs, Boris R. Minev, and Ewa Carrier. "Tumor Stem Cells: Therapeutic Implications of a Paradigm Shift in Multiple Myeloma." In Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures, 349–62. Dordrecht: Springer Netherlands, 2010. http://dx.doi.org/10.1007/978-90-481-9704-0_20.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Dammacco, Franco, Giuseppe Avvisati, Mario Boccadoro, Vito Michele Lauta, Rita Di Stefano, Alessandro Pileri, and Franco Mandelli. "Maintenance Treatment with Recombinant Interferon Alfa-2b Prolongs Remission and Survival in Patients with Multiple Myeloma Responding to Induction Chemotherapy." In Combination Therapies, 67–72. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3340-5_8.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Brault, P., E. Gilles, A. Ibrahim, F. Beaujean, S. Jimenz, G. Tertian, M. Hayat, J. H. Bourhis, and J. L. Pico. "First line chemotherapy for patients with multiple myeloma with vad regimen followed by consolidation with high-dose chemoradiotherapy with peripheral stem cells autograft (PSCA): the experience of IGR center." In Cancer Treatment An Update, 885–88. Paris: Springer Paris, 1994. http://dx.doi.org/10.1007/978-2-8178-0765-2_187.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Baig, Mirza. "Multiple Myeloma." In Practical Radiotherapy and Chemotherapy Planning, 292. Jaypee Brothers Medical Publishers (P) Ltd., 2018. http://dx.doi.org/10.5005/jp/books/13056_40.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

"Chemotherapy, steroids and interferon." In Multiple Myeloma and Related Disorders, 220–40. CRC Press, 2004. http://dx.doi.org/10.1201/b13347-19.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

"Tumours of the haemopoietic system." In Oxford Desk Reference: Oncology, edited by Thankamma Ajithkumar, Ann Barrett, Helen Hatcher, and Sarah Jefferies, 329–92. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198745440.003.0012.

Texte intégral

Résumé :

This chapter covers tumours of the haemopoietic system. Hodgkin lymphoma: clinical features, diagnosis, and staging, treatment of early and advanced stages, management of recurrence, and long-term toxicities and fertility issues are discussed. It outlines current treatment strategies that aim to maintain the high cure rates reached for all stages of the disease with chemotherapy and radiotherapy while further improving outcome and minimizing or preventing therapy-induced complications, such as infertility, cardiopulmonary toxicity, and second malignancies. For non-Hodgkin lymphoma, the clinical features, treatment of low-grade disease, diffuse large B-cell lymphoma, mantle cell lymphoma, cutaneous non-Hodgkin lymphomas, and extranodal involvement are discussed. Diagnosis with molecular profiling is used to define and stratify approaches to treatment for adult acute lymphoblastic leukaemia; adult acute myeloid leukaemia; chronic myeloid leukaemia; chronic lymphocytic leukaemia; hairy cell leukaemia; myelodysplastic syndrome; multiple myeloma; solitary plasmacytoma; monoclonal gammopathy of undetermined significance; smouldering myeloma; Waldenstrom’s macroglobulinaemia; amyloidosis and POEM syndrome; heavy chain disease; and histiocyte disorders.

Styles APA, Harvard, Vancouver, ISO, etc.

9

Derudas, Daniele, and Claudia Concu. "Management of Renal Failure in Multiple Myeloma." In Recent Update on Multiple Myeloma [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.105444.

Texte intégral

Résumé :

Multiple myeloma (MM) is a monoclonal plasma cell neoplasia that commonly involves the kidney. Renal impairment is a serious complication during the course of the disease, and it is associated with increased morbidity and mortality. The most frequent mechanism of injury is represented by the precipitation of monoclonal free light chains (FLCs) in the distal tubule of nephron, defining a dramatic condition known as light chain cast nephropathy (LCCN). A prompt and early identification of the cause of renal disease, particularly in case of acute kidney injury (AKI), is mandatory for its effective management, avoiding the development of chronic kidney disease (CKD). In case of LCCN, in order to achieve renal recovery, it is needed, besides preventive measures, urgent intervention based on vigorous rehydration, correction of precipitating factors and effective anti-plasma cell chemotherapy. Currently, the association of the Proteasome Inhibitor Bortezomib with high-dose of Dexamethasone represents the standard association in newly diagnosed patients. The addition of another drug such as Cyclophosphamide or an Immunomodulatory Drugs may improve FLCs reduction but could be toxic. Interesting is the role of the newest therapeutic agents, particularly anti-CD38 Monoclonal Antibodies, whose efficacy and tolerance have been documented in patients without renal impairment. Despite controversial results from randomized studies, recent data suggest that in patients with LCCN and AKI requiring dialysis the association of systemic therapy with an extra-corporeal approach of FLCs removal, may increase renal response recovery rates. In this chapter, it is summarized physio-pathological basis of MM renal impairment, clinical manifestations, diagnostic procedures, and therapeutic management, included autologous stem cell transplantation.

Styles APA, Harvard, Vancouver, ISO, etc.

10

Heyman, Barbara B. "The Last Years, 1967–1981." In Samuel Barber, 504–53. Oxford University Press, 2020. http://dx.doi.org/10.1093/oso/9780190863739.003.0019.

Texte intégral

Résumé :

During the last fifteen years of his life, Barber struggled with depression, alcoholism, and creative blocks. His publisher believed this was due to the reception of Antony and Cleopatra, but Barber’s annual pilgrimages to Europe had begun much earlier, and it was more likely that the forced sale of Capricorn, the home he and Menotti had shared for three decades, contributed to his low morale. The upheaval was equivalent to the dissolution of a marriage. Money from the Metropolitan Opera commission enabled him to build a chalet in Santa Cristina, where he spent most of his time. He did not withdraw from composing but turned to what had been most gratifying: writing vocal music in short forms, choosing biographically pointed texts reflecting a preoccupation with dark and quasi-religious themes. He produced the song cycle Despite and Still, two choral works, and Mutations from Bach for brass. He wrote Chorale for Ascension Day for the Washington National Cathedral and an elaborate work for chorus, vocal solos, and the Philadelphia Orchestra, The Lovers. A commission for the new Alcoa Hall in Pittsburgh resulted in Fadograph of a Yestern Scene, an orchestral piece inspired by a passage in James Joyce’s Finnegans Wake. Barber composed Three Songs, op. 45, and in 1974 wrote a piano piece, Ballade. That commission allowed him to purchase an apartment overlooking Central Park in New York. In the summer of 1978, he began a concerto for oboe and orchestra, but as his health worsened, he realized he would not be able to complete it and titled the single movement Canzonetta for Oboe and String Orchestra. He was diagnosed with multiple myeloma, and in spite of chemotherapy, Barber died on January 23, 1981.

Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "Multiple myeloma Chemotherapy"

1

Kos, M., K. Geibler, K. Ratheiser, I. Pabinger, Ch Korninger, and K. Lechner. "ACQUIRED FACTOR X DEFICIENCY IN MULTIPLE MYELOMA:A COMPLETE RESPONSE TO CHEMOTHERAPY." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643292.

Texte intégral

Résumé :

A 64 year old women without any previous history of bleeding diathesis presented with bone pain and gastrointestinal bleeding. An isolated severe factor X deficiency (factor X activity 0.5%, factor X antigen less than 12.5%) was found. No inhibitor that inactivated factor X in vitro or interfered with factor X assay could be demonstrated. Substitution therapy with a prothrombin complex preparation containing factor X (PPSB Biotest) was given. Factor X recovery in the first 2 days was lower than expected (below 20%) and half life of factor X was shortened (150 minutes). Subsequently, a diagnosi

Styles APA, Harvard, Vancouver, ISO, etc.

2

Zhang, Xingding, Lin Qi, and Lin Yang. "Abstract 680: HMGB1 regulates autophagy and apoptosis to promote chemotherapy resistance in multiple myeloma." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-680.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Siddiqui, Mohammad F., Sridhar Badireddi, Elias Anaissie, Bart Barlogie, and Federick C. Hiller. "Effect Of High Dose Chemotherapy And Autologous Stem Cell Transplantation On Pulmonary Function In Multiple Myeloma." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a3036.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Gopan, Gayatri, Geetha Narayanan, Sreejith G. Nair, Prakash Purushothaman, Rona Joseph, Rekha A. Nair, and Jagathnath Krishna. "Outcome of Treatment in Elderly Myeloma—A Single-Centre Experience." In Annual Conference of Indian Society of Medical and Paediatric Oncology (ISMPO). Thieme Medical and Scientific Publishers Pvt. Ltd., 2021. http://dx.doi.org/10.1055/s-0041-1735368.

Texte intégral

Résumé :

Abstract Introduction Multiple myeloma (MM) accounts for approximately 1% of all cancers and 10% of all hematologic malignancies. In our institution, we see around 200 patients with myeloma every year. We present our experience with multiple myeloma in the patients aged more than 60 years. Objectives This is a retrospective study of 300 newly diagnosed multiple myeloma patients above 60 years of age treated in the Department of Medical Oncology, Regional Cancer Center, Thiruvananthapuram, Kerala, India, during the period between 2014 and 2017. The medical records of the patients were studied a

Styles APA, Harvard, Vancouver, ISO, etc.

5

Siddiqui, Mohammad F., Sridhar Badireddi, Eilias Annaisie, Bart Barlogie, and Frederick C. Hiller. "Effect Of High Dose Chemotherapy And Autologous Stem Cell Transplantation On Obstructive Lung Disease In Multiple Myeloma." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4474.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Simijonović, Dušica, Marko Antonijević, Edina Avdović, Zorica Petrović, and Zoran Marković. "INHIBITORY EFFECT OF COUMARIN BENZOYLHYDRAZONES ON MCL-1 PROTEIN." In 1st INTERNATIONAL Conference on Chemo and BioInformatics. Institute for Information Technologies, University of Kragujevac, 2021. http://dx.doi.org/10.46793/iccbi21.442s.

Texte intégral

Résumé :

The protein that controls cell differentiation in acute myeloid leukemia is MCL-1. High-level of this protein causes the carcinogenesis. In this paper inhibitory effect of two coumarin benzoylhydrazones,(E)-2-hydroxy-N’-(1-(2-oxo-2H-chromen-3-yl)ethylidene)benzohydrazide (A) and (E)-4-hydroxy-N’-(1-(2-oxo-2H-chromen-3-yl)ethylidene)benzohydrazide (B) against MCL-1 protein was investigated. For this purpose, a molecular docking simulations were used. The obtained results showed that compound A showed better activity than compound B. Also, the docking simulations against MCL-1 protein were perfo

Styles APA, Harvard, Vancouver, ISO, etc.

7

Silva, Ariosto S., Alexander Anderson, Robert Gillies, and Robert Gatenby. "Abstract 21: Understanding the progression and chemotherapy resistance of Multiple Myeloma in the bone marrow through evolutionary computational models and in vitro experiments." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-21.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Shires, Karen, and Kirsty Wienand. "Abstract B18: MAGEC1 and BAGE2 mRNA expression can be used to monitor chemotherapy treatment responses in multiple myeloma patients and pre-empt clinical relapse." In Abstracts: AACR International Conference: New Frontiers in Cancer Research; January 18-22, 2017; Cape Town, South Africa. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.newfront17-b18.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Devi, Pinki, Ganapathi Bhat, and Harish S. Ahuja. "To Predict Success of Postapheresis Yield and Post–Autologous Transplant Engraftment Based on Preapheresis Peripheral Blood CD34+ Cell Counts: An Indian Scenario–Based Study." In Annual Conference of Indian Society of Medical and Paediatric Oncology (ISMPO). Thieme Medical and Scientific Publishers Pvt. Ltd., 2021. http://dx.doi.org/10.1055/s-0041-1735370.

Texte intégral

Résumé :

Abstract Introduction The use of hematopoietic stem cells for autologous and allogeneic transplantation has increased in the recent past significantly, due to introduction of newer chemotherapeutic drugs, immunological techniques, and better stem cell technology. Among the bone marrow and peripheral blood stem cells, collection of the latter being more convenient to the patient and associated with faster granulocyte and platelet engraftment has been known as preferred method for mobilization. Peripheral blood stem cells can be extracted from the autologous or allogeneic donor. Mobilization of

Styles APA, Harvard, Vancouver, ISO, etc.

Rapports d'organisations sur le sujet "Multiple myeloma Chemotherapy"

1

Li, Zonghong, Xuewei Yin, Hongyan Xiao, Chunyi Lyu, Yuping Si, Zhenzhen Wang, Xueyan Dong, Yueli Liu, and Ruirong Xu. Efficacy and safety of bendamustine combined with chemotherapy for relapsed/refractory multiple myeloma A protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0038.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!